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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is a disease with a dismal prognosis, being the 4th 
leading cause of cancer deaths in Sweden and worldwide. The only potentially curative 
therapy is surgery.  Unfortunately, by the time of diagnosis only 20% of patients have a 
resectable tumor and the overall 5-year survival rate does not exceed 5%. One of the main 
reasons for this is that some tumors are not detected, either because of small size or difficulty 
in delineation. Another reason is the underestimation or in some cases overestimation of the 
local tumor staging. These patients undergo an extensive but unnecessary operation or are 
withheld from potentially curative surgery, respectively. In some cases the patients develop 
serious postoperative complications, which can be predicted and perhaps avoided with proper 
preoperative planning. Technological advances in multidetector computed tomography 
(MDCT), combined with its wide availability, have made MDCT the modality of choice for 
PDAC imaging.  
 
The overall purpose of this thesis was to investigate the role of MDCT in patients with PDAC 
in terms of (i) tumor diagnosis, (ii) local staging assessment and (iii) prediction of 
postoperative complications.  
 
In Study I, we compared low-tube-voltage (80 kV) with normal-tube-voltage (120 kV) 
protocols regarding tumor detection by using a phantom that simulated the normal pancreatic 
parenchyma and hypovascular tumors. Our results showed that low tube-voltage significantly 
improves tumor detection. 
In Study II, we evaluated 30 MDCT examinations of the pancreas in patients with PDAC in 
the pancreatic head, obtained according to our institution’s standard protocol (120 kV and 
0.75 g iodine (I)/kg body-weight). Based on our hospital’s classification system, we 
investigated the interobserver agreement among radiologists in local tumor staging 
assessment and the correlation of this assessment to the surgical outcome. Our results showed 
almost perfect agreement among radiologists as well as an increased risk for vascular 
involvement with more advanced preoperative staging.  
In Study III, we compared low-tube-voltage normal-iodine-load (80 kV and 0.75gI) with 
low-tube-voltage high-iodine-load (80 kV and 1gI) and with normal-tube-voltage normal-
iodine-load (120 kV and 0.75gI) protocols in 30 patients with PDAC, regarding tumor 
conspicuity and local vessel involvement. Our results showed that low tube-voltage and high 
iodine-load significantly improve tumor conspicuity.   
In Study IV, we correlated the pancreatic remnant volume (PRV) and pancreatic duct width 
(PDW) in 182 patients undergoing pancreaticoduodenectomy (PDE), to the risk for 
pancreatic leakage and fistula (PF) formation. Our results showed a significantly higher risk 
for PF in patients with high PRV and/or small PDW.  
 
In conclusion, a high-quality preoperative MDCT is a very useful tool in the evaluation of 
PDAC in terms of tumor diagnosis, staging and prediction of postoperative complications. 
The low-tube-voltage high-iodine-load technique has the potential to improve tumor 
diagnosis and local staging.  
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1 INTRODUCTION 
1.1 PANCREAS 
The pancreas is a retroperitoneal organ representing the body’s largest digestive gland 
with both endocrine and exocrine functions [1]. It has a firm, smooth, lobulated surface 
and is anatomically divided into the head, neck, body, tail and uncinate process. The 
neck, which is the portion between the head and the body, is situated anterior to the 
confluence of the portal vein (PV) and superior mesenteric vein (SMV) and is the 
anatomical landmark during the two most common pancreatic surgeries 
(pancreaticoduodenectomy-PDE or so-called Whipple operation and distal 
pancreatectomy-DP) [2]. The body and tail run transversely and slightly upwards with 
no clear-cut margin between them. The tail, which is the most lateral part of the gland, 
lies between the layers of the splenorenal ligament [2]. 
 
Embryologically, the pancreas arises from two buds of the endoderm at the level of the 
duodenal loop [3]. The small ventral bud, which gives rise to the inferior part of the 
head and the uncinate process, rotates dorsally and fuses with the dorsal bud, from 
which comes the superior part of the head, the body and the tail of the gland [3].  
 
The size of the gland varies among populations of the same age and women tend to 
have smaller volumes than men [4]. During childhood and adolescence the pancreatic 
volume increases linearly with age, between 20-60 years reaches a plateau, and then 
declines thereafter [5]. Interestingly, while the total volume of the pancreas decreases, 
an increase in the anteroposterior diameter of the head is often observed [4].  
 
The major part of the gland is exocrine, secreting enzymes for the digestion of 
carbohydrates, lipids and proteins [2]. The endocrine function is responsible for the 
glucose homeostasis, motility and function of the upper gastrointestinal tract [2].  
 
The arterial blood supply of the pancreas derives from branches of the celiac axis (CA), 
superior mesenteric artery (SMA) and splenic artery (SA). The head of the pancreas 
and the uncinate process are supplied by the superior and inferior pancreaticoduodenal 
arcade [6]. The superior pancreaticoduodenal artery arises from the gastroduodenal 
artery (GDA), which is a branch of the common hepatic artery (HA), whereas the 
inferior pancreaticoduodenal artery arises from the SMA [7]. The SA follows a course 
along the superior margin of the body and tail and gives rise to the dorsal pancreatic 
artery, the pancreatic magna and the distal branches to the tail [7].  
 
The venous drainage of the pancreas follows the arteries. Four major 
pancreaticoduodenal veins (anterior and posterior, superior or inferior 
pancreaticoduodenal veins) drain the head into the gastrocolic branch of the SMV, the 
PV, or the jejunal branch of the SMV [8]. Numerous veins drain the body and tail 
directly into the splenic vein (SV) [9]. 
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Lymphatic drainage is extensive. Lymph capillaries originate around the pancreatic 
acini. The lymph vessels, likewise the veins, follow the arteries. Vessels from the tail 
and body drain mostly into the pancreaticosplenic lymph nodes [10]. Lymphatics from 
the neck and head drain into lymph nodes along the pancreaticoduodenal arteries, SMA 
and HA [10]. Occasionally there is direct drainage to the preaortic and CA lymph nodes 
[2]. 
 
 
1.2 PANCREATIC DUCTAL ADENOCARCINOMA 
Pancreatic ductal adenocarcinoma (PDAC), although rare, is the 4th leading cause of 
cancer-related deaths worldwide [11; 12]. It represents 85-90% of all pancreatic 
neoplasms [13]. The only curative therapy is surgery with or without neo- or adjuvant 
radio/chemotherapy, but unfortunately, at the time of diagnosis only 20% of patients 
have a resectable tumor [14]. The overall 5-year survival rate is approximately 5% and 
it can reach 20% only after curative surgery [14]. These percentages have not altered 
significantly over the last two decades despite the technological developments in 
diagnostic imaging or the introduction of more aggressive surgical techniques [15]. It is 
estimated that during 2015 pancreatic cancer-related deaths will be almost as high as 
the reported new cases of pancreatic cancer (40,650 and 48,960, respectively) in the 
United States [15].  
 
The main reasons for PDAC’s dismal prognosis may include: (i) many patients seek 
health care too late, when the tumor is beyond cure, because the debut symptoms are 
often non-specific; (ii) some tumors are not detected, either because of small size or 
difficulty in delineation from the normal pancreatic parenchyma [16; 17]; (iii) the stage 
of the tumor is underestimated, which results in an extensive but unnecessary operation 
with high risk for postoperative complications and in the delayed application of other 
oncologic therapy [18], and (iv) sometimes the extent of the tumor is overestimated, 
which results in potentially curative surgery being withheld from these patients [19].  
 
As already mentioned, the disease debuts with non-specific symptoms, such as 
abdominal epigastric pain radiating into the back, weight loss or new onset diabetes. 
Painless obstructive jaundice with pale stool, dark urine and pruritus are symptoms that 
usually make the patient seek health care but are relatively late symptoms depending on 
the location of the tumor [20]. Smoking and hereditary pancreatitis are two of the most 
common independent predictors of the disease [21].  
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1.3 PANCREATIC DUCTAL ADENOCARCINOMA IMAGING 
Pancreatic imaging in patients with PDAC is mainly used for tumor diagnosis and 
staging. It is also used in selected cases for the detection and monitoring of 
postoperative complications as well as for detection of tumor recurrence. In this 
section, the role of the various imaging modalities of PDAC imaging will be discussed 
with the exception of multidetector computed tomography (MDCT), which is described 
separately in the next chapter.   
 
1.3.1 Abdominal Ultrasound  
Abdominal ultrasound (US) is usually the first-line, non-invasive, cost-effective 
diagnostic tool for patients with abdominal pain or obstructive jaundice [22]. Reported 
sensitivity in the detection of pancreatic cancer varies between 50 - 90% and is highly 
dependent on the operator’s experience and the patient’s body habitus [23]. Regarding 
the assessment of tumor resectability, a recent study yielded a 75% accuracy when the 
examination was performed by experienced ultrasonographers [24]. In our clinical 
experience and that of others [25], US plays an important role in the initial evaluation 
of patients with cholecystitis-like symptoms but has no role in the diagnosis or staging 
of pancreatic cancer.  
 
PDAC typically appears as a solid hypoechoic lesion with ill-defined margins. When 
the tumor is located in the head of the pancreas, a “double duct” sign with dilatation 
of the common bile duct and the main pancreatic duct is often observed [26]. After 
the administration of intravenous contrast medium (CM), PDACs enhance poorly in all 
phases compared to the normal pancreatic parenchyma and the peripancreatic vessels, 
making detection and the resectability assessment more accurate [27]. 
 
1.3.2 Endoscopic Ultrasound  
The main and well-established role of endoscopic ultrasound (EUS), due to its invasive 
nature, is the guided fine needle aspiration (FNA) from pancreatic lesions for cytology 
[28].  
 
The role of EUS in diagnosis and preoperative management is not clear. According to 
one meta-analysis, EUS remains the most accurate method for detecting small (< 3 cm) 
pancreatic tumors, ampullary neoplasms and small (< 4 mm) bile duct stones [29].  
Regarding tumor local resectability, assessment with EUS has shown sensitivity and 
specificity comparable to MDCT [28]. However, there are major limitations such as the 
assessment of the distant extent of the tumor, i.e. liver metastasis and peritoneal 
carcinomatosis. 
 
1.3.3 Magnetic Resonance Imaging  
The role of magnetic resonance imaging (MRI) in the diagnosis and staging of PDAC 
has been debated in recent years. No significant differences were observed 
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between CT and MRI images in the depiction of pancreatic carcinoma (sensitivity 
95% vs 96%, respectively, and specificity 96%, in both) [30; 31]. However, the 
superiority of MRI for small liver metastases detection is indisputable (sensitivity 85 
- 87% vs 69%) [30; 32].  
 
The normal pancreatic parenchyma demonstrates low signal intensity on T2-weighted 
images and high signal intensity on pre-contrast T1-weighted images reflecting the high 
protein content of the exocrine part of the gland [33]. PDAC is hypointense on fat-
suppressed, T1-weighted images before and after gadolinium contrast injection and has 
variable signal intensity on T2-weighted images [34]. On diffusion-weighted images 
(DWI), PDAC has restricted diffusion but this is not tumor-specific [35]. 
 
1.3.4 Positron Emission Tomography/Computed Tomography 
The value of positron emission tomography/computed tomography (PET/CT) in 
pancreatic cancer is still controversial and no consensus has been reached on whether 
and when it should be applied [36]. [18F]-fluorodeoxyglucose (FDG) PET/CT is not 
superior to MDCT for the detection of local lymph node metastases [37]. However, a 
recent study has shown the superiority of PET/CT in the detection of distant metastases 
that are occult with MDCT [38]. Furthermore, it has higher sensitivity regarding bone 
metastasis detection but this is a rare manifestation of the disease [39]. Pancreatic 
malignancies usually have high FDG uptake and appear as “hot spots” within the 
pancreas [23].  
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1.4 MULTIDETECTOR COMPUTED TOMOGRAPHY OF PANCREATIC 
DUCTAL ADENOCARCINOMA 
The best modality for PDAC imaging depends largely on local expertise, preference 
and availability. Recent technical advances in MDCT, permitting high spatial and 
temporal resolution imaging, combined with very wide availability, have made MDCT 
the preferred modality for the radiological evaluation of patients with PDAC [40; 41]. 
Moreover, the International Study Group of Pancreatic Surgery (ISGPS) [42] suggests 
that the preoperative evaluation of tumor resectability should be based on MDCT 
images.  
 
In our institution at the Karolinska University Hospital in Huddinge, which serves as a 
tertiary referral center for pancreatic diseases, a triple-phase MDCT is considered the 
modality of choice in patients with suspected pancreatic cancer whereas MRI has the 
role of the problem-solving modality. 
 
 
1.4.1 MDCT for Diagnosis 
1.4.1.1 The role of MDCT in PDAC diagnosis 
The overall sensitivity of MDCT in tumor diagnosis is reported to be between 86 - 
97%. While MDCT is highly sensitive in detecting large tumors (up to 100% for 
tumors greater than 2 cm), the sensitivity is lower (60 - 77%) for tumors smaller than 2 
cm [16; 17; 43]. Additionally, the tumor size, which is considered as an independent 
prognostic factor [44], may be underestimated in up to 75% of cases, according to a 
recently published study [45]. Furthermore, apart from the tumor size, it has been 
reported that up to 14% of PDACs show similar attenuation with the surrounding 
parenchyma, despite the adequate CT technique, which makes tumor detection quite 
challenging [46; 47]. 
 
1.4.1.2 Image characteristics during diagnosis 
A triple-phase protocol with a non-contrast phase (NCP), a late arterial phase or a so-
called pancreatic parenchymal phase (PPP) and a portal venous phase (PVP) is 
recommended [17]. The PPP is the optimal phase for detecting and delineating PDACs 
because of the higher attenuation difference between the hypovascularized tumor and 
the avidly enhanced parenchyma [48; 49]. An illustrative example is shown in Figure 
1. Due to the high fibrous tissue content, PDAC is visualized as an ill-defined 
infiltrative lesion and shows slight and sometimes delayed contrast enhancement. 
Upstream, either main pancreatic or common bile duct dilatation as well as 
parenchymal atrophy are common (up to 70% of cases) [50] and in some patients, it 
may represent the only finding [51]. 
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Figure 1: Axial MDCT images from a patient with ductal adenocarcinoma in the head of the pancreas in 
the non-contrast phase - NCP (a), the pancreatic parenchymal phase - PPP (b) and the portal venous 
phase - PVP (c). The hypovascularized tumor is not visible in the NCP. It may be suspected in the PVP 
but it is best delineated in the PPP.   
 
 
1.4.2 MDCT for Local Staging 
It is extremely important to use a common, internationally accepted classification 
system in order to provide both clinicians and researchers with a common language for 
pancreatic cancer staging. An optimal classification system should: (i) guide surgical 
planning, (ii) estimate prognosis, and (iii) evaluate treatment response. 
Recent studies have shown that by using structured reports for the assessment of 
pancreatic MDCT, the omission of important information for the surgeons (i.e. vessel 
anatomy variants) is reduced, and this improves surgical planning [52; 53]. 
 
1.4.2.1 The role of MDCT in PDAC staging 
Regarding the assessment of tumor surgical unresectability, several studies have 
demonstrated a high positive predictive value (PPV) with reported values reaching 
100% (90 - 100%) [54; 55]. In practice, that means that almost no patient with 
resectable disease is withheld from potentially curative surgery. However, reported 
PPVs for the assessment of tumor local resectability have varied widely (52 - 96%) 
[54]. This means that there is a group of patients, with unresectable disease, who 
undergo an extensive operation with no benefit.  A meta-analysis including 15 studies 
with an overall total of 1,015 patients has shown that the median probability of 
unresectable disease being incorrectly diagnosed as resectable is 40% [56]. Taking this 
data into consideration, 4 out of 10 patients undergo an unnecessary laparotomy. This 
meta-analysis includes older studies with incomplete CT protocols and older CT scans. 
More recent studies have yielded higher specificity of tumor resectability reaching 90% 
[57]. 
 
1.4.2.2 Image characteristics during staging 
If distant metastases (i.e. liver or lung) or peritoneal carcinomatosis are absent, a 
detailed description of the major peripancreatic vessels’ involvement is mandatory in 
order to assess the local tumor staging and thus tumor resectability. The two main 
parameters traditionally used for evaluating vessel involvement are the grade of the 
circumferential surface [58] and the length of the vessel with which the tumor is 
contiguous [59]. In order to avoid inconsistency in the description of vessel 
involvement in this thesis, the MD Anderson’s Cancer Center definition has been 
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adopted: if tumoral involvement of the vessel circumference is ≤180° or >180°, the 
word abutment or encasement is used, respectively [59].  
 
1.4.2.3 Different Classification Systems 
The World Health Organization (WHO) [60] and the American Joint Committee on 
Cancer (AJCC) [61] recommend the “TNM” classification system for pancreatic cancer 
staging, where T refers to tumor, N to lymph nodes and M to metastases. According to 
this classification, the T status divides the tumors as intrapancreatic (T1: <2 cm and T2: 
>2 cm) and extrapancreatic (T3: without or T4: with SMA or CA involvement). Even 
though this classification system is a very useful tool for postoperative evaluation of the 
patient’s prognosis, it does not include the role of venous involvement nor have any 
precise definition of “vessel involvement", which make it insufficient for preoperative 
assessment of tumor resectability [62]. 
 
Lu and Loyer were almost simultaneous pioneers correlating the tumor’s relationship to 
the main peripancreatic vessels and tumor resectability.  Lu et al. described the 
likelihood of tumoral vascular involvement based on the percentage of circumferential 
surface contact between the tumor and the vessel, concluding that more than 180° of 
tumor-vessel contact is highly specific for tumor unresectability [58]. Loyer et al. 
proposed a more descriptive classification, again based on the extension of the 
hypodense tumor and its relationship to the main peripancreatic vessels (Table 1) 
[63]. Both studies showed an increased risk for vessel involvement and therefore an 
increased risk for the need for vessel resection or tumor unresectability with 
increasing circumferential tumoral involvement of the vessel. However, these 
classifications do not take into account the length of the vessel that is contiguous to 
the tumor or the differences between venous and arterial involvement. Additionally, 
they do not differentiate between per continuitatem tumor growth around the vessel 
and perivascular stranding, which does not necessarily consist of tumoral tissue [64].  
 
 
 
 
 
 
 
 Table 1. Loyer’s classification of vascular involvement in PDAC 
Type   Tumor’s relationship to the major peripancreatic vessels 
A  Fat plane separates the tumor from adjacent vessels 
B  Normal parenchyma separates the tumor from adjacent vessels 
C  Tumor against the adjacent vessel forming a convexity 
D  Tumor against the adjacent vessel forming a concavity 
E  Tumor encircling the adjacent vessel 
F  Tumor occluding the adjacent vessel 
 Loyer et al. Abdominal Imaging. 1996 May-June; 21(3): 202-6 
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The definition of pancreatic cancer resectability has changed over recent decades. 
This is mainly due to two reasons: firstly, due to the development of new surgical and 
more aggressive therapeutic approaches allowing vessel resection and reconstruction 
with survival rates comparable with those of patients undergoing surgery without vessel 
resection [65] and secondly, due to the introduction and wide use of neoadjuvant 
therapies with high probability for negative resection margins (R0) after operation. 
These reasons necessitated the introduction of new classification systems that have an 
impact on the immediate therapeutic management.  
 
In 2006, the MD Anderson’s Cancer Center introduced a new classification system by 
adding a third category of tumors other than “resectable” and “unresectable” ones, 
called “borderline” (Table 2) [59]. Their main goal was to optimize preoperative 
treatment and minimize the risk of falsely categorizing a tumor as 
unresectable/locally advanced. They stated that the end point for the analysis of tumor 
resectability should be the negative resection margins (R0). Regarding SMA, they 
stated that vessel abutment or periarterial stranding categorize the tumor as 
“borderline” because complete resection is more likely. Even short-segment 
encasement of the HA, usually at the GDA origin, allows vascular resection with a 
high probability of R0-resection.   
 
Table 2. MD Anderson Cancer Center’s criteria for resectability assessment of 
pancreatic cancer 
Vessel      Resectable    Borderline     Locally advanced 
SMA No extension Abutment 
Periarterial stranding or 
convexity against the 
vessel 
Encased 
CA/HA No extension Short-segment 
encasement/abutment 
of HA typically at the 
GDA origin 
Encased and no technical 
options for reconstruction 
usually because of extension 
to the CA 
SMV/PV Patent Short-segment 
occlusion with suitable 
vessel above and below 
Occluded and no technical 
option for reconstruction 
SMA: superior mesenteric artery; CA: celiac axis; HA: hepatic artery; SMV: superior mesenteric vein; 
PV: portal vein; GDA: gastroduodenal artery. 
Varadhachary et al. Annals of surgical Oncology 2006 Aug; 13(8): 1035-1046 
 
In 2009, MD Anderson Cancer Center’s classification system was adopted by the 
National Comprehensive Cancer Network (NCCN) with minor changes (Table 3) 
[66]. The main difference between these two classification systems is that abutment 
or encasement of SMV/PV is considered as “borderline” by the latter and 
straightforward resectable by the former. 
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Table 3. The National Comprehensive Cancer Network’s criteria for resectability 
assessment of pancreatic cancer (version 1.2014) 
Resectable Borderline resectable Unresectable 
No distant metastasis No distant metastasis Distant metastasis 
No radiographic evidence 
of SMV/PV distortion 
SMV/PV involvement with 
distortion, narrowing or 
occlusion with suitable 
vessel above and below 
allowing resection and 
replacement 
Unreconstructible SMV/PV 
occlusion 
Clear fat planes around 
CA, HA and SMA 
GDA encasement up to HA 
with either short-segment 
encasement or abutment of 
the HA 
SMA encasement 
CA abutment/encasement 
Aortic or IVC encasement or 
invasion 
 SMA abutment  
CA: celiac axis; GDA: gastroduodenal artery; HA: hepatic artery; IVC: inferior vena cava; PV: portal 
vein; SMA: superior mesenteric artery; SMV: superior mesenteric vein. 
Tempero et al. J Natl Compr Canc Netw 2014 Aug; 12(8): 1083-93 
 
 
These resectability criteria are given only for PDAC in the head of the pancreas. 
However, the presence of CA abutment/encasement does not preclude tumor resection 
in tumors located in the body and tail of the pancreatic gland [67]. In those cases en-
bloc tumor and CA resection is recommended if the SMA, GDA and proper HA are 
free from the tumor.   
 
1.4.2.4 Our Hospital’s Classification System 
In recent years a CT-based classification system has been introduced at the 
Karolinska University Hospital, based on principles of surgical resectability (Table 
4). It takes into consideration both venous and arterial involvement with regard to the 
vessel circumference and length that is contiguous to the tumor. The importance of 
both parameters (circumference, length) differs between arteries and veins: i.e. even 
up to 360° involvement of a short SMV/PV segment is easier to deal with compared 
with corresponding involvement of the SMA or CA. Furthermore each category is 
correlated to a therapeutic management process. Based on radiological imaging, 
tumors in category A1 do not attach to any major vessel and it is considered unlikely 
that any vessel resection would be needed. Tumors in category A2 abut a limited 
segment of SMV/PV and vein resection is potentially required. Tumors in categories 
B1 and B2 encase a short segment of SMV/PV or abut a short segment of HA, 
respectively. Vessel resection is more probable. Tumors in category C show a more 
advanced vessel involvement and neoadjuvant therapy is recommended in most of 
these cases. Finally, category D tumors are considered locally advanced/unresectable 
and palliative therapy is almost always offered.  
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Table 4. Our hospital’s classification for resectability assessment of pancreatic cancer 
 Vein-SMV/PV Artery Management 
A1 None None Primary resectable 
without vessel 
reconstruction 
 
A2 ≤180° None Primary resectable  
with minor risk of vein 
reconstruction 
 
B1 >180° and ≤2cm None Primary resectable  
with probable need of 
vascular reconstruction 
 
B2 Any of the above  HA≤180° and ≤2cm 
C >180° and >2cm &/or SMA or CA ≤180° and 
≤2cm 
“Borderline”: probably 
resectable after 
neoadjuvant therapy 
 
D Total occlusion or 
encasement of 
mesenteric branch 
HA or SMA or CA >180° or 
>2cm or  
encasement of mesenteric 
branching 
Unresectable  
SMV: superior mesenteric vein; PV: portal vein; HA: hepatic artery; SMA: superior mesenteric artery; 
CA: celiac axis. 
 
 
1.4.3 MDCT for Prediction of Postoperative Complications 
PDE remains the only curative therapy for patients with PDAC but it is associated with 
significant postoperative morbidity [68]. The most common complication responsible 
for this increased morbidity is the formation of a postoperative pancreatic fistula (PF) 
due to leakage from the pancreatico-enteric anastomosis [69]. The PF is graded from A 
to C based on the definition of the International Study Group on Pancreatic Fistula 
(ISGPF) [70]. According to this classification, grade A is the presence of a biochemical 
leakage. Biochemical leakage is defined as the output containing pancreatic amylase on 
or after the third postoperative day from a surgically positioned drain, displaying 
pancreatic amylase more than three times the upper serum reference value. Grade B is 
defined as clinically significant leakage such that therapeutic intervention is required. 
In Grade C severe clinical sequelae are present.  
 
Several risk factors have been defined and validated, such as soft or fatty pancreas and 
small caliber pancreatic duct [71]. Most of these factors can only be objectively 
assessed at the time of surgery and are, by necessity, observer-dependent to a certain 
degree. The role of somatostatin analogs as inhibitors in the secretion of pancreatic 
digestive juices has not been established.  
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Modern radiological techniques may facilitate the risk prediction of PF formation in a 
preoperative setting [72]. A recent study at our institution suggested an increased PF 
risk after DP in patients presenting with large pancreatic remnant volume (PRV) and 
small radiological pancreatic duct width (PDW) [73]. 
 
 
1.4.4 MDCT Protocol Issues 
As mentioned above, the best phase for PDAC diagnosis and delineation is the PPP 
where the attenuation difference between the normal pancreatic parenchyma and the 
tumor is highest. The role of PVP is limited to the assessment of the tumor’s 
relationship to the main peripancreatic veins (PV/SMV) and to the evaluation of the 
hepatic parenchyma for detecting liver metastases. Two parameters influencing the 
pancreas-to-tumor attenuation difference are the tube voltage of the scanner and the 
total iodine load of the injected CM.  
 
1.4.4.1 Parameters regarding the CT scanner: tube voltage 
Tube voltage at 120 kV is considered standard in abdominal imaging at our institution 
and many others [74-77]. By reducing tube voltage from 120 kV to 80 kV, the mean 
photon energy of the X-ray beam is reduced from 56.8 to 43.7 keV, which is closer to 
the k-edge of iodine (33.2 keV). This phenomenon leads to higher X-ray absorption 
and, consequently, to higher attenuation of materials with a high atomic number such as 
iodine-containing structures [78]. This attenuation increase is achieved by an increased 
photoelectric effect (complete X-ray absorption) and decreased Compton scattering (X-
ray scatter with fractional loss of X-ray energy) [79]. In addition, low-tube-voltage CT 
scanning has the ability to decrease the radiation dose, which is of major clinical 
importance. This principle has been used in thoracic [80] and heart [81] CT as well as 
in CT examinations of patients with low body mass index and of children [82]. In 
recent years, the technique has also been used to improve CT angiography of the 
pulmonary arteries [83] and the detection of hypervascular liver lesions [78]. Recently, 
a dual-energy (DE) MDCT study showed potential improvement in tumor conspicuity 
at 80 kV in terms of optimized pancreatic and peripancreatic vasculature enhancement 
[84]. However, the main drawback of low-tube-voltage MDCT is the increased image 
noise, which may have an impact in image quality. 
 
1.4.4.2 Parameters regarding the contrast medium 
The main parameters regarding CM are the total iodine load, the iodine concentration, 
the injection rate and duration as well as the scan delay.  
The patient’s body weight is correlated to the pancreatic and liver parenchymal 
enhancement: in heavier patients the enhancement is significantly lower compared to 
thinner patients if the same fixed volume of CM is administered [85]. For this reason a 
body-weight-tailored CM dosage is preferable rather than a fixed dosage [86; 87] due 
to comparable enhancement between thinner and heavier individuals.  
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The volume of the injected CM is subject to considerable variation and has traditionally 
been determined empirically. Heiken JP et al. showed that the volume should be at least 
0.52g Iodine (I)/kg body weight for optimal liver attenuation and detection of 
hypovascular liver metastasis [88]. Yamashita et al. have shown that 0.75g I/kg body 
weight is superior to 0.6g I/kg and 0.45g I/kg body weight for liver and pancreatic 
imaging, respectively [89].  
 
An increase in the iodine concentration –with the total iodine mass and injection rate 
kept constant– leads to shorter injection duration, smaller CM volume and higher 
iodine mass per unit time. Consequently that means earlier and greater peak aortic 
enhancement, in the time-density curve, without any significant effect on the 
parenchymal enhancement of the liver [90]. For instance, if we administer a highly 
concentrated CM – 400mg/ml – to a patient weighting 70 kg at a body-weight-tailored 
dosage of 0.75gI/kg and a fixed injection rate of 5ml/s, the total CM volume should be 
130 ml and the injection duration 26s. If we choose the same CM at a lower 
concentration – 300mg/ml – the volume should be increased at 175 ml and, 
consequently, the injection duration should be prolonged at 35s.  
 
The enhancement kinetics of the pancreas follows the arterial dynamics due to its 
entirely arterial blood supply from branches direct from the abdominal aorta [91]. 
Several studies have revealed the superiority of high concentration CM in terms of 
pancreatic parenchymal and peripancreatic vessel attenuation [92-94]. In addition, 
another advantage of a highly concentrated CM is the shorter injection time for a given 
volume [92]. 
 
Apart from CM concentration, the second most important parameter influencing the 
arterial enhancement is the CM injection rate. Schueller et al. have shown that a high 
injection rate (8ml/s) compared to a low one (4ml/s) of a fixed CM volume at an 
individualized scan delay (using bolus tracking), leads to a more rapid iodine load and 
to an increase in the magnitude of the peak pancreatic parenchymal attenuation. 
However, the pancreatic tumor attenuation does not differ significantly, which 
contributes to an increase in the parenchyma-to-tumor contrast [95]. Conversely, the 
magnitude of liver enhancement reaches a “plateau” with relative low injection rates 
(>2 ml/s), which means that liver parenchymal attenuation is independent of the 
injection rate and, thus, cannot be optimized accordingly [91].  Moreover, a high 
injection rate provides greater temporal separation between the PPP and PVP and this 
distinct phase separation is beneficial for multiphase scanning of the liver and pancreas 
[90]. 
 
At this point it is important to emphasize that changing the iodine concentration of the 
CM has the same proportional effect on arterial enhancement as changing the injection 
rate [90; 91]. 
 
The injection duration is defined as the CM volume divided by the injection rate. If the 
volume of the injected CM is relative high (i.e. if we administer body-weight-tailored 
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dose in heavier patients) and the injection rate is fixed, the injection duration will be 
prolonged with the risk that the scanning will start during the CM injection. For that 
reason fixed injection duration is preferable than fixed injection rate [96] especially in 
the cases of body-weight-tailored dosages. Yanaga suggested that using fixed injection 
duration in body-weight-tailored dosage protocols reduces the variation in the aortic 
peak time and aortic peak enhancement value [85]. The arterial and thus pancreatic 
enhancement increases cumulatively with the injection duration [91].  
 
Scan timing is critical. A recent study revealed that 20-second and 30-second delays 
(with a body-weight-tailored volume and injection rate of 4ml/s) after the aortic transit 
time (150 HU) are superior to 10 seconds, whereas the pancreatic enhancement and the 
tumor-to-parenchyma contrast are higher [97]. 
 
In summary, a high injection rate of a highly concentrated CM at a fixed duration leads 
to an increase in the magnitude of peak vascular enhancement and to a better separation 
of the arterial and venous phases. However, the volume of the injected CM contributes 
foremost to the magnitude of liver enhancement. Taking into consideration the 
literature mentioned above, the optimal combination of CM parameters could be a 
body-weight-tailored dosage of 0.6 - 0.75g/I of a highly concentrated CM (more than 
300mg/ml) that is injected at a high injection rate with at least a 20-second delay after 
the aortic transit time.  
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2 AIMS 
 
The aims of this thesis were to investigate the role of MDCT in the: 
 
1. Detection of PDAC by comparing normal- with low-tube-voltage imaging 
protocols (Studies I and III) 
 
2. Assessment of local tumor staging by 
 
a. Estimating the interobserver agreement among radiologists in assessing vessel 
involvement and predicting resectability using a normal-tube-voltage protocol 
and our institution´s classification system (Study II) 
b. Comparing normal- with low-tube-voltage protocols in assessing vessel 
involvement (Study III), and 
 
3. Prediction of postoperative complications by correlating PRV and PDW with 
the risk of pancreatic leakage and fistula formation after PDE (Study IV). 
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3 METHODS AND MATERIALS 
Studies II, III and IV were approved by the regional ethics review board. An ethics 
permit was not needed for Study I.  
 
3.1 STUDY POPULATION 
Study I  
One hundred simulated patient cases were created by using a phantom, which simulated 
the normal pancreatic parenchyma (Catphan® 600, The Phantom Laboratory, Salem, 
USA). The phantom was mounted into a body annulus (CTP579) to better simulate the 
size of the human trunk. In 57 of these cases, 1 to 3 spherical hypodense lesions were 
digitally inserted in random positions: 2, 3, 4, 5, 6, 8 and 10 mm in diameter.   
 
Study II 
Thirty patients (18 men and 12 women, mean age 68 years) were recruited 
retrospectively, between October 2006 and December 2010, from a register of 277 
consecutive patients undergoing PDE for various pathologies. Inclusion criteria: (i) CT 
examination of the pancreas according to our institution’s standard protocol (PS) (Table 
6), (ii) patients assessed as having a potentially resectable hypovascularized tumor in 
the pancreatic head by the multidisciplinary tumor board and (iii) histopathologically 
verified PDAC. Exclusion criterion: administration of neoadjuvant therapy. 
 
Study III 
Thirty patients (14 men and 16 women, mean age 66 years) were recruited 
prospectively, between February 2010 and September 2014, from 235 consecutive 
patients assessed as having a potentially resectable hypovascularized pancreatic tumor 
by the multidisciplinary tumor board. Informed consent was obtained from each 
patient. Inclusion criterion: histopathologically verified PDAC. Exclusion criteria: (i) 
body weight higher than 85 kg, (ii) estimated GFR lower than 60 ml/min/1.73 m2, (iii) 
undergoing neoadjuvant therapy. The tumor was located in the pancreatic head in 25 
patients and in the body/tail in the remaining five patients. Data from a previous study 
on attenuation differences between parenchyma and tumor in patients with PDAC were 
used for performing power analysis [79]. 
 
Study IV  
One hundred eighty two patients (94 men and 88 women, mean age 66 years) were 
recruited retrospectively, between September 2007 and November 2010, from a register 
(the same as in Study II) of 197 consecutive patients undergoing PDE for various 
pathologies. Inclusion criterion: presence of an adequate CT/MR examination of the 
pancreas. Exclusion criteria: (i) administration of neoadjuvant therapy and (ii) extended 
resection.  
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3.2 IMAGE ACQUISITION 
Our institution’s 64-channel MDCT scanners (LightSpeed VCT or LightSpeed VCT 
XTE, GE Healthcare, Milwaukee, USA) were used for all the CT examinations in 
Studies I, II and III. In Study IV, examinations from different institutions were included 
as long as the image quality for the study purpose was adequate.  
 
Iomeprol 400 mg I/ml (Iomeron-400, Bracco Imaging SpA, Milan, Italy) or iodixanol 
320 mg I/ml (Visipaque-320, GE Healthcare, Chalfont St. Giles, UK) were the two 
non-ionic iodinated CM used in Studies I, II and III. In Study IV the concentration of 
the CM was variable (320-400 mg I/ml).  
 
Study I  
The Catphan® 600 phantom was scanned 3 times with 3 different protocols: protocol A 
(PA), protocol B (PB) and protocol C (PC) as described in Table 5. In PA, the tube 
voltage was set at 120 kV. In PB and PC the tube voltage was decreased to 80 kV. In 
PB, the radiation dose was kept the same as in PA, while in PC, it was increased to 
achieve the equivalent image noise as in PA.  All the other scanning parameters not 
mentioned in Table 5 were kept constant and were the same as in the PPP of our 
institution’s PS (Table 6). The reconstruction slice thickness and interval were 3 mm 
and 1.5 mm respectively, corresponding to the PS’s reconstructions with a narrower 
FOV. The total number of images per simulated patient case was 21.  
 
The attenuation of the simulated normal pancreatic parenchyma at PA (120 kV) was set 
at 130 (SD=3.5) HU after measurements in PPP in 15 clinical pancreatic MDCT 
examinations according to PS (120 kV and 0.75 g I/kg body-weight). We assumed that 
the simulated lesions’ attenuation differed from the background by only 20 HU and 
thus the lesions’ attenuation was set at 110 HU. To estimate the corresponding 
attenuation for the parenchyma and the lesions at 80 kV, six different concentrations of 
CM (Iomeron-400) were diluted with water (1.1, 2.2, 3.2, 4.3, 5.4 and 6.5 mg I/ml 
water) in standard 10 ml plastic vials. These were inserted into the center position of a 
phantom (RMI Model 461A, Gammex/RMI, Middleton, USA), which was scanned at 
120 kV and 80 kV. The attenuation values were plotted against the iodine concentration 
and correlated linearly (Figure 2). The corresponding attenuation values for the lesions 
and the parenchyma at 80 kV were 183 HU and 217 HU, respectively.  
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Figure 2. The mean attenuation (HU) for the six test tubes containing different iodine concentrations 
scanned at 120 kV and 80 kV. 
 
Study II 
All 30 patients underwent a CT examination of the pancreas according to our 
institution’s PS (Table 6).  
 
Study III 
All 30 patients underwent two CT examinations of the pancreas. Following a CT 
examination according to the institution’s PS (n=30), patients were randomized to two 
groups: (i) protocol D (PD, n=14; 80 kV and 0.75 g I/kg body weight) and (ii) protocol 
E (PE, n=16; 80 kV and 1 g I/kg body weight). The mean time interval between the two 
CT examinations was 15 (SD=7.5) days. The three protocols are briefly described in 
Table 6. For each patient, the serum creatinine level was measured before every 
examination and three days after the second examination. None of the patients showed 
signs of contrast-induced nephropathy. 
 
Study IV 
From the 182 patient examinations, 167 were MDCT and the remaining 15 MRI. All 
the examinations included at least a PPP and a PVP. The slice thickness varied between 
3 mm (with a reconstruction interval of 1.5 mm) and 5 mm (with a reconstruction 
interval of 2.5 – 5 mm). 
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3.3 SCANNING PROTOCOLS 
Our institution’s PS as well as PA, PB, PC, PD and PE are illustrated in Tables 5 and 6. 
 
Table 5. CT protocols in Study I 
Protocol  Tube voltage 
(kV) 
Tube current 
(mA) 
CTDIvol 
(mGy) 
Noise 
(HU) 
PA 120 160 15 15 
PB 80 500 15 17 
PC 80 675 20 15 
PA: protocol A; PB: protocol B; PC: protocol C; CTDIvol: computed tomography dose index volume. 
 
Table 6. Our institution’s standard protocol (PS) used in Studies II and III and Protocol 
D (PD) and Protocol E (PE) used in Study III 
Protocol Standard 
(PS) 
PD PE 
 
Preparation 
 
Fasting for 4 hours 
Oral Contrast  1,000 ml tap water, 30 min prior to examination 
 
Intravenous Contrast 
a. volume - gI/kg body weight 
b. injection duration - s 
c. I concentration - mg/ml 
d. NaCl flush 
 
 
0.75 
25 
400/320 
50 ml-5ml/s 
 
 
0.75 
25 
400/320 
50 ml-5ml/s 
 
 
1 
25 
400/320 
50 ml-5ml/s 
 
Scan timing and range 
a. NCP 
b. PPP 
 
c. PVP 
 
 
Upper abdomen 
Upper abdomen: 20 s after bolus tracking reached 160 HU in the 
aorta at the level of the first lumbar vertebra 
Upper abdomen and pelvis: 25 s after the end of PPP scan 
 
Scanning parameters 
a. collimation (mm) 
b. table feed (mm) 
c. tube voltage (kV) 
d. tube current (mA) 
e. rotation time (s) 
f. pitch 
g. kernel  
 
PPP/PVP 
0.625 
20/39 
120 
ATCM 
0.6 
0.5/0.98 
soft 
 
PPP/PVP 
0.625 
20/39 
80 
ATCM  
0.6 
0.5/0.98 
soft 
 
PPP/PVP 
0.625 
20/39 
80 
ATCM 
0.6 
0.5/0.98 
soft 
 
Reconstructions 
a. slice thickness 
b. interval 
 
Axial, coronal and sagittal 
5 mm (& 3 mm with narrower FOV focused on pancreas) 
2.5 mm (& 1.5 mm with narrower FOV focused on pancreas) 
I: Iodine; NCP: non-contrast phase; PPP: pancreatic parenchymal phase; PVP: portal venous phase; 
ATCM: automatic tube current modulation; FOV: field of view. 
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3.4 IMAGING ASSESSMENT  
A standard picture archiving and communicating system (PACS) workstation (Sectra, 
Linköping, Sweden) was used for imaging assessment in all studies. 
In addition, a Voxar® 3D workstation (Toshiba Medical Visualization Systems, 
Edinburgh, UK) with 3D segmentation and volume calculation was used for the PRV 
estimation in Study IV.  
 
Study I 
Three radiologists, with 24, 21 and 7 years of experience in the interpretation of CT 
examinations, blinded to the examination protocols and lesion characteristics, evaluated 
the 100 cases per protocol, independently and twice: first with fixed and then with free 
window settings. However, they were not allowed to use the zoom tool. To minimize 
the memory effect, for each protocol and each session the 100 cases were rearranged. 
 
For each protocol and case each reader: 
(i) marked the suspicious lesion/lesions with an arrow and  
(ii) graded the confidence level on a four-point scale (1: probably not a lesion, 2: 
possibly a lesion, 3: probably a lesion, 4: definitely a lesion).  
 
Study II 
Nine radiologists, grouped as trainees, experienced and experts according to their years 
of experience in abdominal imaging (1-2 years, 5-6 years and >10 years, respectively) 
blinded to the surgical outcome, evaluated the 30 cases, independently. They were free 
to change the window settings and the zoom level at their preference as they would in 
clinical practice.  
 
For each examination, they assessed the tumor involvement of the major peripancreatic 
vessels (PV/SMV, CA, HA and SMA) as well as of the mesenteric venous or arterial 
branching, addressing the: 
(i) maximal percentage of the circumference, and  
(ii) maximal length that was contiguous to the tumor.  
 
Based on these evaluations, the tumors were classified by one of the readers into a 
category according to our hospital’s classification system (Table 7). 
For the correlation to the surgical outcome, consensus between three of the nine readers 
was obtained in those cases where less than 6 readers classified the tumor in the same 
category.  
Finally, for the correlation to the R0 rate (%) and median survival the categories were 
grouped due to the small sample size: group 1, primarily resectable tumors with no 
contact to major peripancreatic vessels (category A1); group 2, primarily resectable 
tumors with limited contact to major peripancreatic vessels (categories A2, B1 and B2); 
and group 3, primarily non-resectable tumors (categories C and D). 
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Study III 
Two radiologists with 15 and 6 years’ experience in abdominal imaging, blinded to the 
examination protocols as well as to the surgical and histopathological findings, assessed 
all 60 examinations independently in random order for the qualitative analysis.  
For each protocol and examination, each reader assessed:   
(i) the tumor delineation on a four-point-scale (1: absent, 2: poor, 3: clear, 4: sharp),  
(ii) the tumor involvement of the major peripancreatic vessels (PV/SMV, CA, HA and 
SMA) as well as of the mesenteric venous or arterial branching. The vessels were 
considered encased/abutted if more/equal or less than 180° of their circumference was 
in contact with the tumor, based on the criteria defined earlier [58] and as in Study II, 
and  
(iii) the image quality on a four-point scale (1: poor, 2: acceptable, 3: good, 4: 
excellent).  
The image quality was based on the sharpness of demarcation of the upper abdominal 
organs, the clarity of the mesenteric fat and the overall diagnostic impression.   
 
A third radiologist with 3 years’ experience in abdominal imaging assessed the images 
for the quantitative analysis.  
For each protocol, examination and contrast-enhanced phase she measured the:   
(iv) attenuation of the normal pancreatic parenchyma,  
(v) attenuation of the tumor, and  
(vi) standard deviation of the attenuation of the subcutaneous fat in the anterior 
abdominal wall. 
 
The measurements were obtained by manually drawing three circular regions of interest 
(ROIs) to encompass as much of the parenchyma, tumor and subcutaneous fat as 
possible in the axial plane. Areas of necrosis, cystic formations, dilated ducts and 
vessels were avoided. For each patient, measurements were performed simultaneously 
and at the same level on both examinations and imaging phases to ensure consistency. 
The three measurements per parenchyma and tumor were averaged and used for the 
estimation of the: 
(vii) parenchyma-to-tumor attenuation difference,  
(viii) parenchyma-to-tumor contrast-to-noise ratio (CNR), using the formula: 
CNR = (mean parenchyma - mean lesion attenuation)/noise, whereby noise was the 
mean value of the standard deviation (SD) of the subcutaneous fat attenuation, and  
(ix) figure of merit (FOM) using the formula: FOM = CNR2/ED [84], whereby ED is 
the effective radiation dose. The FOM was estimated because direct comparison of the 
CNRs between the different protocols was not possible due to the fact that the radiation 
dose could not be kept constant when ATCM was applied.  
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Study IV  
Two radiologists with 20 and 2 years’ experience in abdominal imaging, blinded to the 
postoperative outcome, calculated in consensus:  
(i) the PRV – the pancreatic volume at the left of the SMV – and 
 (ii) the PDW – at the transection line.  
The volumetric analyses were performed in the axial plane (Figure 3) and in the 
contrast phase with the best delineation of the parenchyma (PPP in most of the cases) 
from the surrounding vessels. In 10 of the patients, the two radiologists calculated the 
volume separately and the interindividual variation was less than 10%.  
 
 
Figure 3: This is a CT examination performed according to our institution’s standard protocol (PS) in a 
patient with ductal adenocarcinoma in the head of the pancreas. The four images show how the pancreatic 
remnant volume was estimated. With a semiautomatic segmentation technique, the pancreas can be 
delineated (green line), first at the level of the alleged resection line (blue arrow) and then several sections 
toward the tail (image b). The intermediate sections are automatically bordered (blue areas).  
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3.5 CLASSIFICATION SYSTEMS 
In Study II, our hospital’s classification system (Table 4) was applied for both the 
interobserver variability assessment and the correlation to the surgical outcome.  
In Study III, the correlation of the major peripancreatic vessels’ involvement with the 
surgical and histopathological outcome was based on the criteria proposed by Lu et al. 
[58] The vessels were considered encased/abutted if more/equal or less than 180° of 
their circumference was in contact with the tumor. 
 
 
3.6 SURGICAL PROCEDURE 
In all clinical studies (II, III and IV), all patients underwent surgical exploration with 
curative intent. Experienced and fully trained pancreatic surgeons familiar with the 
techniques of major vessel resection and reconstruction performed all the operations. 
The pre- and perioperative management was standardized as far as possible. 
In Study II, 28 of the 30 patients underwent PDE (of these, 10 with SMV/PV resection, 
one with HA resection and one with HA and SMV/PV resection) and two patients 
underwent palliative by-pass surgery (due to vessel involvement).  
In Study III, 23 out of the 30 patients underwent PDE (of these, eight with SMV/PV 
resection and one with SMV/PV and HA resection), two DP (of which one underwent 
SMV/PV resection and en-bloc CA resection) and five patients had palliative by-pass 
surgery (due to occult liver metastases and/or peritoneal carcinomatosis).  
In Study IV, all 182 patients underwent PDE.  
The mean time between examination and surgery was 23 (SD=14) days, 19 (SD=9) 
days and 40 (SD=29) days for Studies II, III, and IV, respectively.  
 
 
3.7 HISTOPATHOLOGICAL ANALYSIS 
All the specimens were evaluated in a standardized manner [98]. 
In Studies II and III, all the patients included had a histopathologically verified PDAC.  
In Study III, the resected vessel segments were evaluated for the presence of 
microscopic wall infiltration. Of the 10 patients undergoing SMV/PV resection, eight 
showed evidence of wall infiltration whereas in both patients undergoing HA and CA 
perivascular tumor infiltration was found. 
In Study IV, the majority of the patients (133/182, 73%) were diagnosed with PDAC. 
The next three most common diagnoses were neuroendocrine tumor (10/182, 5.5 %), 
pancreatitis (12/182, 6.6 %) and IPMN (10/182, 5.5 %). The rest of the diagnoses were 
gastric cancer, serous cystadenoma, pancreatic intraepithelial neoplasia (PanIN) 1-2, 
villous adenoma and gastrointestinal stromal tumor (GIST).  
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3.8 POSTOPERATIVE COMPLICATIONS – PANCREATIC FISTULA  
In Study IV, the estimated PRV and PDW were correlated to the postoperative outcome 
and specifically to the development of pancreatic leakage and fistula formation (PF), as 
this is defined in the introduction section. In the same study, the modified Clavien-
Dindo scoring system [99] was used for the classification of the  overall postoperative 
morbidity. 
 
 
3.9 RADIATION DOSE MEASUREMENTS  
In Studies I and III, the estimated radiation dose was used for comparison, due to the 
fact that the scanner’s tube voltage varied between the compared protocols.   
In Study I, the volume CT dose index (CTDIvol) was measured by using a pencil 
ionization chamber (DCT10, Wellhöfer, Germany) inside a 32 cm body phantom. The 
results are presented in Table 5.  
In Study III, the CTDIvol and dose length product (DLP) were provided by the CT 
scanner. The effective dose (ED) was estimated by multiplying the DLP by a 
conversion factor of 0.0153 for 120 kV examinations and 0.0151 for the 80 kV 
examinations [100]. The results are presented in the results section.  
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3.10 STATISTICAL ANALYSES 
Study I 
DBM-MRMC software version 2.2 was used for the statistical analysis [101]. The 
study was analyzed using the receiver operation characteristic (ROC) method and 
calculating a figure of merit (FOM) for each reader and protocol [102]. Multiple 
comparisons of continuous data were performed by analysis of variance (ANOVA). 
In the case of a statistically significant result, statistical comparisons were made by 
using the post-hoc test to control for multiplicity as proposed by Fisher. Because the 
ROC methodology cannot handle information about the number of lesions per case and 
their localization, the lesion localization fraction (LLF) and the non-lesion localization 
fraction (NLF) were calculated using the formulas:  
i) LLF=LL/n, whereby LL is the lesion localization defined as a mark no more than 1 
cm from the lesion and n is the total number of lesions, and  
ii) NLF=NL/n, whereby NL is the non-lesion localization defined as a mark located 
more than 1 cm from a lesion and n is the total number of cases. 
 
Study II 
For the interobserver agreement, the intraclass correlation coefficient (ICC) was 
calculated according to the method presented and described by Shrout & Fleiss [103] 
and Bland & Altman [104]. A score between 0–0.2 indicates poor agreement, 0.3–0.4 
indicates fair, 0.5–0.6 indicates moderate, 0.7–0.8 indicates strong and more than 0.8 
indicates a very strong and almost perfect agreement. The correlation between the 
imaging assessment and the surgical outcome, R0 rate and median survival was done 
with descriptive statistics. 
 
Study III 
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for the statistical 
analysis. ANOVA and post-hoc analysis (t-test) were performed as described in Study 
I. In order to evaluate hypotheses of variables in contingency tables, the Chi-square test 
was used or, in the case of small expected frequencies, Fisher's exact test. The Pearson 
correlation coefficient was used in order to test independence between variables. In 
addition to that, descriptive statistics were used to characterize the data.  
 
Study IV 
The statistical analysis was performed using SPSS 19.0 software (SPSS Inc., Chicago, 
IL, USA). All tests of statistical significance were two-sided. Pearson’s Chi-square and 
the Spearman correlation test were used for categorical values. Logistic regression 
analyses were performed to identify risk factors for pancreatic fistulae, with and 
without simultaneous adjustment for competing risk factors. Crude associations were 
studied in a univariate model, which was followed by a multivariate analysis of the 
respective factors.  
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4 RESULTS 
4.1 STUDY I 
The highest reader-averaged FOM was acquired for PC using a free-choice window 
setting. The lowest reader-averaged FOM was acquired for PA, using a free-choice 
window setting. The FOMs for each reader and protocol are presented in Table 7.  
 
 
 
The reader-averaged FOM differed significantly (P<0.0001), which means that at least 
two protocols differed. The results of the post-hoc analysis are presented in Table 8. 
 
 
 
 
Table 7. FOMs for each reader and protocol and the reader-averaged FOM 
 Protocols 
 120 kV           80 kV 120 kV          80 kV 
 PA PB PC PA* PB* PC* 
Reader 1 0.720 0.785 0.840 0.706 0.771 0.833 
Reader 2 0.741 0.795 0.836 0.704 0.807 0.842 
Reader 3 0.679 0.829 0.834 0.716 0.842 0.876 
Average 0.713 0.803 0.837 0.709 0.807 0.850 
* free window setting; FOM: figure of merit; PA: protocol A; PB: protocol B; PC: protocol C. 
Table 8. Inter-protocol comparison  
Protocol comparison Δ FOM P-value 
C* - A* 0.1419 <0.0001 
C* - A 0.1372 <0.0001 
C - A* 0.1283 <0.0001 
C - A 0.1237 <0.0001 
B* - A* 0.0979 0.0003 
B - A* 0.0943 0.0005 
B* - A 0.0933 0.0006 
B - A 0.0897 0.0010 
C* - B 0.0475 0.0797 
C* - B* 0.0439 0.1053 
C - B 0.0340 0.2097 
C - B* 0.0304 0.2621 
C* - C 0.0135 0.6174 
A - A* 0.0046 0.8644 
B* - B 0.0036 0.8941 
*: free window setting;  Δ FOM: differences between the figures of merit. 
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Tumor detection was significantly better with the 80 kV protocols (PB and PC) 
compared with the 120 kV protocol (PA).  No significant difference was obtained 
between the two 80 kV protocols or between the fixed and the free window setting. 
 
 
 
Figure 4. Images of the phantom scanned at 120 kV (a, c) and 80 kV (b, d) with the same image noise. 
Images (a) and (b) depict a 10 mm lesion and images (c) and (d), a 5 mm lesion (black arrow). The 10 
mm lesion is visualized in both protocols. However, the parenchyma-to-lesion attenuation difference is 
higher and the subjective lesion delineation is better at 80 kV (b). The 5 mm lesion can hardly be 
delineated at 120 kV (c).  
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For the descriptive statistics the LLF is presented in Figure 5. 
 
 
Figure 5: The reader-averaged lesion localization fraction (LLF) for each lesion size and protocol (*: free 
window setting; ^: fixed window setting; C: protocol C; B: protocol B; A: protocol A) 
The bar graphs in Figure 5 show that all protocols are good and equal for detecting 
lesions 8 and 10 mm in diameter.  The 80kV protocols are superior to the 120kV 
protocol for detecting 5 and 6 mm lesions. For lesions smaller than 5 mm, no protocol 
revealed satisfactory results.   
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4.2 STUDY II 
The overall ICC showed almost perfect agreement between radiologists with different 
levels of expertise in local vessel assessment in patients with PDAC in the head of the 
pancreas. Results are presented in Table 9.  
  
Table 9. The interobserver variability for each reader group and overall 
Group ICC 
Trainees 0.846 
Experienced 0.759 
Experts 0.919 
Overall 0.94 
ICC: intraclass correlation coefficient. 
 
In 22 of the 30 patients, six or more readers classified the tumor in the same category. 
In the remaining 8 patients, consensus was obtained between three readers (one from 
each level of expertise). The distribution of the vascular resection in the different 
categories is presented in Table 10.  
 
Table 10. Radiological staging as related to subsequent vascular resection 
Category     Number                                   Surgical report 
                   of patients                                 
  No 
vessel 
resection 
Vein 
resection 
Artery 
resection 
Artery + 
vein 
resection 
Unresectable 
A1 9 9     
A2 10 6 4    
B1 0      
B2 2 1 1    
C 3 1 2    
D 6  2 1 1 2 
 
In all nine tumors classified as category A1 no sign of vascular invasion was 
observed during surgery. In 40% of tumors classified as category A2 (4/10), a 
corresponding infiltration of the SMV/PV was observed and a resection of the 
respective vessel was found to be necessary. In category B2, one of the two tumors 
(50%) required SMV/PV resection. Two out of three tumors (67%) in category C had 
corresponding vein resections. All six patients with tumors classified as category D 
had signs of vascular involvement during surgical exploration. Two of them (33%) 
had a locally advanced tumor deemed to be unresectable.  
Finally, the R0 rate was 33%, 25% and 0% in group 1, 2 and 3, respectively. The 
median survival was 20, 22 and 12 months in group 1, 2 and 3, respectively.   
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4.3 STUDY III 
Significantly better tumor delineation (clear - sharp) in PD (86%) and PE (87.5%) 
compared to PS (65%) (P=0.02). Results are presented in Table 11.  
In two patients, one of the readers deemed the tumor not visible in PS and poorly or 
clearly visible with PE and PD, respectively (Figure 6). At 80 kV, all tumors were 
deemed as visible.  
 
Table 11. Comparison of the parameter “tumor delineation” between the three 
protocols (PS, PD and PE) for each reader and overall 
 PS PD PE P-value 
 None/ 
poor 
Clear/ 
sharp 
None/ 
poor 
Clear/ 
sharp 
None/ 
poor 
Clear/ 
sharp 
 
Reader 
1 
7/30 
23% 
23/30 
77% 
2/14 
14% 
12/14 
86% 
3/16 
19% 
13/16 
81% 
0.7 
        
Reader 
2 
14/30 
47% 
16/30 
53% 
2/14 
14% 
12/14 
86% 
1/16 
6% 
15/16 
94% 
0.006 
        
Overall 
21/60 
35% 
39/60 
65% 
4/28 
14% 
24/28 
86% 
4/32 
13% 
28/32 
87% 
0.021 
1PS vs. PD: P=0.04; PS vs. PE: P=0.02; PD vs. PE: P=0.8. PS: standard protocol; PD: protocol D; PE: 
protocol E.  
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Figure 6. Coronal MDCT images of a patient with ductal adenocarcinoma in the head of the pancreas 
(open arrow) during the pancreatic parenchymal (a, b) and portal venous (c, d) imaging phases. Images 
(a) and (c) were obtained at 80 kV (normal iodine-load; protocol D) whereas (b) and (d) were obtained 
at 120 kV (PS). For both readers, delineation of the tumor was clear with PD and poor or absent with 
PS, respectively. Superior opacification of mesenteric branches (arrowheads) during both imaging 
phases in the 80 kV (a, c) compared to the 120 kV examinations (b, d) may also be observed. A 
common bile duct stent is indicated by the black arrow. 
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No significant difference was observed between the three protocols regarding 
assessment of vessel involvement. For Readers 1 and 2, the accuracy of PS, PD and 
PE for vessel assessment was 95/91%, 92/94%, and 92/90%, respectively. 
All three protocols resulted in a slight overestimation of HA involvement (Figure 7). 
In four patients (one from Reader 1, two from Reader 2 and one from both readers), 
the HA was assessed as encased with PS. In only one patient, a short segment of HA 
was resected and perivascular tumor infiltration was observed microscopically. In one 
patient using PD (both readers) and one using PE (Reader 2), the HA was assessed as 
encased but none of these patients required a HA resection. 
 
 
Figure 7: Axial (a, b) and coronal (c, d) MDCT images of a patient with ductal adenocarcinoma in the 
head of the pancreas (open white arrow) during PPP. Images (a) and (c) were obtained with PD 
whereas (b) and (d) were taken with PS. Both readers assigned hepatic artery (HA) encasement 
(arrowhead) by the tumor at the origin of the gastroduodenal artery (black arrow) in both examinations. 
During surgery, no signs of infiltration of the HA were present. 
 
No significant difference was found between the protocols in both PPP and PVP in 
image quality. PPP in PS, PD, and PE was graded as excellent in 87%, 79%, and 69% 
of cases, respectively. The rest of the cases were graded as good. Image quality was 
not graded as poor or acceptable in any of the cases. PVP in PS, PD, and PE was 
graded as excellent in 78%, 50%, and 58% of cases, respectively. In each protocol, 
PD and PE, one case was graded as acceptable (4%). The rest of the cases were 
graded as good. 
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The pancreatic parenchymal/tumor attenuation, parenchyma-to-tumor attenuation 
difference as well as the parenchyma-to-tumor CNR and FOM are presented in Table 
12. 
 
Table 12. Comparison between the three protocols (PS, PD and PE) for the 
parameters parenchyma-tumor attenuation, parenchyma-tumor attenuation 
difference, parenchyma-to-tumor CNR and FOM 
 PS PD PE P-value 
PS vs PD      PS vs PE        PD vs PE 
PPP (SD) 
Parenchyma HU 150 (29) 232 (47) 298 (55) <0.0001        <0.0001          <0.0001 
Tumor HU 90 (24) 125 (23) 140 (47) <0.0001         <0.0001 0.26 
Attenuation  
difference HU 
59 (28) 89 (45) 158 (72) 0.01               <0.0001               0.005 
CNR 8 (4) 9 (5) 15 (8) 0.34                 0.0002 0.02 
FOM 6 (6) 11 (9) 36 (41) 0.03 0.002 0.03 
PVP (SD) 
Parenchyma HU 116 (16) 180 (35) 231 (28) <0.0001         <0.0001             0.0008 
Tumor HU 86 (18) 121 (38) 145 (40) 0.0002           <0.0001                 0.14 
Attenuation  
difference HU 
30 (21) 60 (36) 85 (47) 0.002              <0.0001                0.15 
CNR 3 (2) 4 (3) 5 (4) 0.05 0.003 0.4 
FOM 2 (3) 5 (6) 7 (10) 0.03 0.01 0.5 
SD: standard deviation; PPP: pancreatic parenchymal phase; PVP: portal venous phase; CNR: 
parenchyma-to-tumor contrast-to-noise ratio; FOM: figure of merit. 
 
In both imaging phases, pancreatic parenchymal attenuation was highest in PE and 
the difference from PD and PS was statistically significant. The measurements of 
tumor attenuation in the two imaging phases were comparable for all three protocols. 
In PPP, the parenchyma-to-tumor attenuation difference and parenchyma-to-tumor 
CNR were significantly higher in PE compared to PD and PS. In the same phase, i.e. 
PPP, the normalized parenchyma-to-tumor CNR as expressed by FOM was 
significantly higher in PE and PD as compared to PS.  
 
The mean parenchyma-to-tumor attenuation difference in PE in PVP is similar to 
attenuation difference in PD in PPP and higher than the attenuation difference in PS 
in PPP. 
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The radiation dose was significantly higher for PS compared to PD and PE. The mean 
CTDIvol, mean DLP and mean ED for all the protocols (for both PPP and PVP) are 
described in Table 13.  
 
 
Table 13. Comparison between the three protocols (PS, PD and PE) for radiation dose 
parameters 
 PS PD PE P-value 
CTDIvol, in mGy (SD) 52 (18) 35 (10) 34 (10) 
1,2 0.003 
3 0.9 
     
DLP, in mGy x mm (SD) 1660 (626) 1160 (426) 1100 (318) 
1 0.02 
2 0.006 
3 0.7 
     
ED, in mSv (SD) 25 (9) 18 (6) 17 (5) 
1 0.01 
2 0.004 
3 0.7 
1: PS vs. PD. 2: PS vs. PE. 3: PD vs. PE. CTDIvol: computed tomography dose index dose index; DPL: 
dose length product; ED: effective dose; SD: standard deviation  
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4.4 STUDY IV 
In total 120 patients (66%) out of the 182 experienced postoperative complications 
(Clavien >1) and 31 (17%) of them had a severe complication (Clavien ≥ 3b). The most 
common complication was PF. All the postoperative complications are described in 
Table 14.  
 
Table 14. Postoperative complications and pancreatic fistula formation (PF) after 
pancreaticoduodenectomy  
Complication Number of patients (%) 
Pancreatic fistula 
Grade A 
Grade B 
Grade C 
38 (20.9) 
3 (1.6) 
21 (11.5) 
14 (7.7) 
Abscess 24 (13.2) 8 without PF 
Intra-abdominal bleeding 13 (7.1) 5 without PF 
GI bleeding 6 (3.1) 5 without PF 
Delayed gastric emptying  16 (8.8) 14 without PF 
Bile leakage 8 (4.4) 5 without PF 
Lymph leakage 6 (3.3) 6 without PF 
Sepsis 4 (2.2) 2 without PF 
Pulmonary embolism 3 (1.7) 3 without PF 
Reoperation 24 (13.2) 13 without PF 
Death 3 (1,6) 1 without PF 
 
The mean PRV was 36.9 (SD=15.5) cm3 (Figure 8). The mean PDW was 4.6 (SD=3.0) 
mm (Figure 9). Corresponding values at the 25th, median, and 75th percentiles were 
24.9, 35.2, and 46.7 cm3 for PRV and 2.1, 3.9, 7.1 mm for PDW, respectively. No 
patient with PRV at the 1st quartile developed a clinically significant PF (grade B or C). 
Only one patient with PDW in the 75th quartile developed PF.  
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Figure 8: Distribution of pancreatic remnant volume (cm3) in patients with or without grade B and C 
fistula. 
 
 
 
Figure 9: Distribution of pancreatic duct width (mm) in patients with or without grade B and C fistula. 
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Logistic regression analyses were performed to identify potential determinant variables 
(Table 15). In the multivariate analyses, a large PRV or small PDW significantly 
increases the risk for PF, independently.  
 
Table 15. Univariate and multivariate analyses of risk factors for grade B and C PF 
Variable Number of 
PF (%) 
Univariate analysis Multivariate analysis 
  OR 95%CI P 
value 
OR 95%CI P 
value 
1PRV-cm3        
<35.2 8/75(9.4) 1 1.58-8.71 <0.01 1 1.27-6.27 <0.01 
≥35.2 27/97 (27.8) 3.71   2.55   
PDW-mm        
<3.9 30/91 (33.3) 8.46 3.11-23.04 <0.01 6.94 2.51-19.23 <0.01 
≥3.9 5/91 (5.5) 1   1   
Female 11/88 (11.4) 0.49 0.27-1.05 0.07    
Male 22/94 (23.4) 1      
Diabetes 2/26 (7.7) 0.35 0.078-1.56 0.17    
BMI 20-30 29/152 1 1 0.58    
BMI >30 2/16 (18.8) 0.65 0.140-3.0 0.31    
BMI <20 1/14 (7.1) 0.34 0.04-2.7     
Malignant 23/144 (16.0) 0.61 0.26-1.46 0.27    
Benign 9/38 (23.7) 1 1     
R1-resection 11/77 (14.3) 0.67 0.30-1.48 0.32    
1: Cutoff at the median value. PF: pancreatic fistula; PRV: pancreatic remnant volume; PDW: pancreatic 
duct width; BMI: body mass index; OR: odds ratio; CI: confidence interval. 
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5 DISCUSSION 
This thesis was intended to evaluate the role of 64-channel MDCT on pancreatic cancer 
diagnosis (Studies I and III), local staging assessment (Studies II and III) and prediction 
of postoperative complications (Study IV). More specifically, the roles of the current 
institutional standard examination protocol (Studies I, II and III) and classification 
system (Study II) were investigated. Additionally an attempt to improve tumor 
diagnosis (Studies I and III) and local staging assessment (Study III) was made by first 
using an experimental model (Study I) and afterwards conducting a prospective 
randomized clinical study (Study III), in order to study the effect of lowering the tube-
voltage and increasing the iodine-load.  
 
5.1 DIAGNOSIS  
The late arterial phase or so-called pancreatic parenchymal phase is well known as the 
optimal phase in which to detect and delineate the majority of pancreatic cancers. The 
rationale behind this is the higher attenuation difference between the hypovascularized 
fibrotic tumor and the avidly enhanced normal pancreatic parenchyma compared to the 
other scanning phases. The reasoning for using a low-tube-voltage protocol was to 
study whether tumor conspicuity can be improved by achieving a higher attenuation 
difference between the simulated digital lesions and the background for Study I, and 
between the tumor and the normal pancreatic parenchyma for Study III. When the tube 
voltage is decreased from 120 kV to 80 kV, the mean photon energy decreases in 
parallel from 56.8 to 43.7 keV [78] which is closer to the K edge of iodine (33.2 keV) 
resulting in higher X-ray absorption and a significantly higher attenuation of iodine-
containing tissues. Consequently, the attenuation difference between the simulated 
lesions and the background – Study I – and between the tumors and the pancreatic 
parenchyma – Study III – increases by 70% (from 20 HU to 34 HU) and 51% (from 59 
HU to 89 HU), respectively. However, the increase in attenuation difference in Study 
III becomes even higher (168%) when both low tube-voltage and high iodine-load are 
combined.  Even though the attenuation of both parenchyma and lesion increases 
gradually between normal-tube-voltage, low-tube-voltage and low-tube-voltage high-
iodine-load protocols, respectively, the relative increase of the parenchymal 
attenuation is predominant, which results in a significantly higher attenuation 
difference.  
 
The results of the phantom Study I showed the superiority of low-tube-voltage 
protocols regarding the detection of small hypoattenuating tumors. It has been revealed 
that both low-tube-voltage and normal-tube-voltage protocols are equal and adequate 
for detecting lesions 8 and 10 mm in diameter in an optimal experimental environment. 
However, smaller lesions (5-6 mm) are easily missed with the normal-tube-voltage 
protocol but may be detected by decreasing the scanner’s tube voltage. 
 
The results of the randomized prospective Study III showed the superiority of a low- 
tube-voltage high-iodine-load MDCT protocol regarding tumor conspicuity in 
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patients with pancreatic cancer. The tumor’s borders become sharper as the image 
contrast decreases and, despite the increase in image noise, image quality is not 
compromised. Even though the subjective evaluation of tumor conspicuity yielded no 
significant difference between the low-tube-voltage normal-iodine-load and low-tube-
voltage high-iodine-load protocols, the objective attenuation difference expressed in 
terms of CNR and FOM, is higher when a combination of both parameters is applied. 
 
An interesting and unexpected finding was the higher parenchyma-to-tumor 
attenuation difference in PVP of the low-tube-voltage high-iodine-load protocol (PE) 
(85 ± 47, mean ± SD) compared to PPP of the normal-tube-voltage normal-iodine-
load protocol (PS) (59 ± 28, mean ± SD). The clinical implication of this result is that 
the PVP obtained with the optimized protocol could eventually replace the PPP. In 
that way, both the examination time and the radiation dose can be decreased.   
 
 
5.2 LOCAL STAGING 
Staging of patients with pancreatic cancer using MDCT is central to their clinical 
management. Based on the fact that surgery with or without radiochemotherapy is the 
only curative treatment for PDAC, it is critical that the preoperative radiological 
examinations provide accurate information in order to reach the optimal therapeutic 
decision for the individual patient.  
 
The results of Study II showed strong agreement between radiologists regardless of 
their level of expertise in assessing the tumor involvement of the major peripancreatic 
vessels using our institution’s MDCT standard examination protocol (120 kV and 
0.75 g I/kg) and based on our hospital’s classification system (A1 to D). Although a 
slight variation was seen in the ICC values between the three groups of radiologists, 
trainees, experienced and experts (ICC values of 0.85, 0.76, and 0.92 respectively), 
this was not deemed clinically significant.  
 
The second major finding of Study II showed that as the classification goes from A1 
to D (in practical terms translating into progression of the local tumor stage), the 
degree of vascular involvement and the probability of en-bloc vascular resection or 
surgical unresectability increase. In this context, a subgrouping of the A and B 
categories (Table 4) is proposed based on the assumption that these categories lead to 
important alterations in the planning of a therapeutic strategy. Recently, there has 
been an attempt to divide category D into D1 and D2, distinguishing those patients 
who have a technically resectable tumor (D1 i.e. no engagement of the mesenteric 
branching or hepatic artery bifurcation) and may benefit from neoadjuvant treatment 
from those that do not (D2). Further prospective studies are needed to investigate the 
potential impact of this differentiation on patients’ short- and long-term survival.  
 
At a first glance, this classification system may look complex, consisting of different 
interconnecting elements. However, the objective is to reflect reality and basically 
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cover the clinically relevant combinations of venous and/or arterial involvements. 
Each vessel is evaluated separately and when this assessment is completed, each 
patient is placed in the respective category (from A1 to D). Furthermore, the results 
from younger, less experienced radiologists suggest that our classification system is 
easy to learn and use. 
 
The definition of surgical resectability of PDAC has changed in recent decades. This 
is mainly due to the introduction of new, more aggressive surgical techniques 
allowing vessel resection and reconstruction (i.e. resection of the mesenterico-portal 
axis or short-segment resection of the HA as well as CA resection in distal tumors). 
However, the classification system proposed by Lu [58], which takes into 
consideration the circumference of the vessel that is contiguous to the tumor, remains 
the cornerstone of the most widely used and accepted classification systems for the 
assessment of the main peripancreatic vascular involvement. In Study III, we chose to 
correlate the assessment of vascular involvement to the surgical and histopathological 
outcome based on Lu’s classification and not to our department’s classification 
system as in Study II, for two reasons. First, our department’s classification (A1 to D) 
reflects a probability for vascular resection in each group, which make it impossible 
to compare the radiological imaging findings with the actual vascular status (gold 
standard). Second, our classification system was developed for tumors located in the 
head of the pancreas, whereas in Study III patients with distal tumors were also 
included.  
 
The results of Study III showed similar vessel involvement assessment between normal 
tube-voltage and low-tube-voltage with or without high-iodine-load protocols. One 
interesting finding from this study is the overestimation of the extent of arterial 
involvement, predominantly of the HA, a finding which corresponds with the results 
from another recent study [19]. This is the reason why the International Study Group 
of Pancreatic Surgery recommends surgical exploration in cases where the HA 
appears encased on preoperative imaging [42]. 
 
In Study III, two patients showed histopathological signs of periarterial tissue 
infiltration (HA and CA respectively). Arterial wall involvement is rarely observed 
due to the rigidity of the arterial wall compared to the venous, while perivascular 
infiltration is more common. Surgical resection is, however, warranted in both 
instances. For that reason, both vessels were considered as infiltrated in the imaging 
analysis. 
 
In Studies II and III, the population was limited to patients diagnosed with potentially 
resectable PDAC undergoing surgery with curative intent. Our intent was to investigate 
tumor resectability as we did not consider the investigation of tumor unresectability 
relevant due to the results of previous studies that showed a PPV as high as 100%.  
Moreover, in order to correlate the preoperative vascular involvement assessment with 
the surgical and histopathological outcome, surgical exploration was mandatory. 
However, this choice can lead to a selection bias with the risk of overestimating the 
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accuracy of all MDCT protocols regarding the assessment of vessel engagement 
because the anticipated extent of the vascular involvement in our series was much 
lower compared to that of the unselected cohort of patients with PDAC. The evaluation 
of the vascular involvement in patients belonging to more advanced categories/stages, 
and specifically the interobserver variability assessment, is the subject of an ongoing 
study at our institution.  
 
Neoadjuvant therapy can potentially alter the radiological evaluation. A recent study 
showed that classical resectability criteria could not be used in this group of patients 
[105]. Hence, we excluded all those patients receiving any kind of neoadjuvant therapy 
from all the clinical studies (Studies II, III and IV). 
 
 
5.3 PREDICTION OF POSTOPERATIVE COMPLICATIONS 
The results of Study IV showed that high PRV and/or small PDW at the transection line 
after PDE are significantly and independently correlated with a high risk of 
postoperative PF. The association between the preoperative estimated PRV/PDW and 
the incidence of non-clinically significant grade A PF as well as clinically significant 
grade B and C was observed.  
 
Obviously, the PF rate and morbidity in general are substantial after PDE, as seen in 
this series, as well as in many other recent reports from high-volume centers [106]. It is 
also evident, although complication rates are high, that these complications can be 
managed successfully with low in-hospital mortality and a decent length of hospital 
stay. Two main theories underlie the findings of Study IV. First, while the normal 
pancreatic tissue is being replaced by fibrosis, the volume decreases and the duct 
diameter increases [107]. A recent study from our institution revealed a close 
relationship between the preoperative PRV and PDW estimation and the related 
intraoperative assessment of the gland texture and PDW in predicting postoperative PF 
[108].  Second, the larger the gland the more digestive juice produced per unit time and 
this compromises the healing of the pancreatico-enteric anastomosis. 
 
 
5.4 TECHNICAL CONSIDERATIONS 
Our main consideration by decreasing the tube voltage in both Studies I and III is the 
increase of image noise. To overcome and test this potential limitation in Study I, in 
one of the two low-tube-voltage protocols (PC), we maximized the tube current (675 
mA) in order to achieve equivalent image noise as in the normal-tube-voltage protocol 
(PA). The results revealed no significant difference in tumor detection between the two 
low-tube-voltage protocols. In Study III, even though the radiation dose was decreased 
in the low-tube-voltage protocols, despite the higher tube-current, and the image noise 
was increased, the image quality was not compromised.   
 
  43 
Increasing the scanner’s tube current consequently increases the radiation dose to the 
patient. The risk of developing a radiation-induced cancer is markedly age-dependent. 
The median age of PDAC diagnosis is 71 years and the overall 5-year survival rate is 
less than 5% [109]. If we take these facts into consideration, the risk for this group of 
patients of developing a radiation-induced cancer as a result of a MDCT-related 
increase in radiation dose is essentially negligible. However, there is a group of healthy 
individuals with either predisposing or genetic factors associated with increased risk for 
PDAC that undergoes screening routinely. The radiation dose should be taken into 
account in these patients and new, simplified but high specificity techniques should be 
developed. At our institution there has been an attempt to shorten the CT examination 
protocol for these patients by scanning the pancreas only in the PPP.  
 
In our standard institutional MDCT protocol we use 0.75 g I/kg body-weight, which 
has been shown to be superior to lesser iodine dosage levels in liver and pancreatic 
imaging [89]. In protocol PE, further increasing the iodine load to 1 g I/kg body-
weight was found to be of great clinical benefit. To the best of our knowledge, there 
are no previous studies testing such a high dosage of CM.   
 
In Study I, two of the three readers did not generate an appreciable amount of NLs for 
the 80kV protocols with the free-window setting and thus the statistical analysis 
became less reliable. For that reason a ROC analysis was performed even though the 
initial study design was based on free-response ROC (FROC). The highest rated mark 
per case was used for the ROC evaluation. Complementary descriptive statistics were 
done so that the information about the location and the number of lesions was not lost. 
The ROC methodology is considered very powerful because it estimates and reports all 
combinations of sensitivity and specificity that a diagnostic test is able to provide [110]. 
 
In both Studies II and III, the scanner’s tube current was set by automatic tube current 
modulation (ATCM). The ATCM technique combined with a proper noise index to 
maintain an adequate image quality has the potential to reduce the total radiation dose 
level [40]. The maximum level was set at 800 mA and 675 mA for the 120 kV and 80 
kV protocols, respectively, which represents the maximum tube current that our 64-
channel MDCT can generate in the respective tube voltage levels.  
 
 
5.5 LIMITATIONS 
Study I 
The ideal spherical shape of a tumor in the ideal homogenous background does not 
reflect daily clinical practice. PDAC is an infiltrative, fibrotic tumor that sometimes 
hardly delineates from the normal pancreatic parenchyma and peripancreatic tissues. 
Furthermore, approximately one out of 10 tumors is isoattenuating compared to the 
normal pancreatic parenchyma even in the PPP. The attenuation used as a reference in 
Study I for pancreatic parenchyma (130 HU) and pancreatic cancer (110 HU) at 120 kV 
was measured in a limited number of patients (n=15). However, in Study III the mean 
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attenuation of the pancreatic parenchyma and pancreatic cancer in PPP at the same tube 
voltage were 149 HU and 90 HU respectively and the mean attenuation difference was 
59 HU. These results show that the mean parenchymal attenuation measured in a larger 
group of patients (n=30) was close to that chosen for Study I. On the other hand, the 
mean attenuation of the tumor and the mean pancreas-to-tumor attenuation difference 
were lower and higher, respectively, revealing that the Study I hypothesis reflects only 
a few cases in clinical practice, quite close to the “worst case scenario”, i.e. tumors that 
have attenuation similar to the parenchyma.  
 
Technical issues concerning the CT scan and image processing are some further 
limitations of this study. Overweight/obese patients are not suitable for 80 kV MDCT 
because of the high image noise which cannot be optimally compensated for by the 
maximal increase in the radiation dose. Furthermore, the simulated tumors were 
inserted into reconstructed images, meaning that the lesions were not affected by the 
modular transfer function (MTF) of the system. In future studies, the lesions may 
instead be convolved with the point-spread function (PSF) before inserting them into 
the images in order to avoid this inconsistency. 
 
Study II 
One major limitation of Study II is the limited number of cases in some groups and 
subgroups. In our attempt to have the most homogenous study material possible, with 
all examinations being state-of-the-art, only 30 patients were eligible for inclusion. 
Indeed, category B1 (SMV/PV involvement >180° and ≤ 2 cm) does not contain a 
single patient. Moreover, only three of the 30 patients (10%) were classified as 
category C following the consensus image reading. There were also only a few 
patients classified as category D. Additionally, due to the small sample size, statistical 
comparison between the different categories and the outcome could not be performed. 
Therefore further studies with larger patient populations, including a substantial 
number of patients with locally advanced tumors, are needed to determine the 
relevancy of this subgrouping and the applicability of this classification system for 
more locally advanced disease.  
 
Another potential limitation is that the present classification system was based 
entirely on the relationship between the tumor and the adjacent major peripancreatic 
vessels, in the absence of distant metastasis or peritoneal spread. This does not mean 
that the tumor's relationship to the remaining three-dimensional anatomical structures 
in the area is prognostically or therapeutically irrelevant. Future studies, especially 
when combined with dedicated, highly specialized pathology reporting, must address 
these issues and their clinical significance. Based on the results of such studies, 
further refinement and adjustments of the present PDAC classification system might 
be required. However, tumor resection with negative resection margins as an 
indicator of curative surgery is possible even in cases where adjacent organs, such as 
the stomach and/or colon are infiltrated.  
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Furthermore, concerns could be potentially raised about the CT technique used during 
the study period between October 2006 and December 2010 and the possibility of 
using a more recent patient group in order to have CT examinations of higher quality 
due to the rapidly evolving MDCT technology. As stated in the methods section, all 
patients were examined with the same 64-channel MDCT scanner using the same 
examination protocol, which is the standard protocol currently used in our 
department. However, bearing in mind the results of Study III, new, larger, 
prospective, well-designed studies should be conducted in order to correlate this 
classification system to surgery in CT examinations obtained with the optimized low-
tube-voltage high-iodine-load protocol.  
 
Study III 
A potential limitation of our study is the fact that in nine patients there was a slight 
variation in the rotation time during the acquisition of PPP at 80 kV (1 second instead 
of the predetermined level of 0.6 seconds), which is a potentially important technical 
parameter. By increasing the rotation time the radiation dose increases and the image 
noise decreases, which may lead to an overestimation of tumor conspicuity during 
those 80 kV examinations. We decided, however, to include data from these nine 
patients because comparing the CDTIvol between the 80 and 120 kV examinations, it 
was shown that the radiation dose level of the 80 kV examinations did not reach the 
dose level of 120 kV, even though the rotation time was 1 second. 
 
Study IV 
The preoperative examinations used for volume measurements were those closest to the 
operation. That led to an inhomogeneous study group with examinations from different 
institutions, different modalities (CT or MRI) and different acquisition protocols (i.e. 
variable slice thickness). However, according to Reiner et al. [111] although the mean 
total liver volume decreases with increased slice thicknesses for both CT and MRI, the 
difference is not significant if slice thickness is up to 6 mm for CT and 8 mm for MRI. 
Our protocols were within those limits. In 25 patients those measurements were done 
by means of MRI images. In 10 of them MDCT examinations were available within a 
time frame of ≤ 1 month and comparison of the volume measurement revealed no 
statistically significant differences: mean PRV with MDCT 34.4 (SD=10.0) cm3 and 
with MRI 33.3 (SD=8.4) cm3.  
 
It is important to state that in the PRV the volume of the pancreatic duct is included, 
which may falsely increase the volume of parenchyma. In patients with an atrophic 
pancreatic parenchyma, a dilated main pancreatic duct often coexists, as both can be 
consequences of an obstructive expansive process downstream. So the difference 
between the total PRV and the parenchyma volume after subtraction of the volume of 
the dilated duct may be large in these patients. From a clinical point of view, 
measurement of the entire remnant volume is achievable, but additional measurement 
of the volume from which the duct is deducted would be time-consuming and, thus, 
hard to pursue in daily clinical practice. 
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5.6 CLINICAL CONSEQUENCES  
In Study I, the main clinical consequence of our findings is that the low-tube-voltage 
MDCT technique has the potential to improve the detection of smaller PDACs in 
patients with suspected pancreatic cancer, which may not be visible in the normal-tube-
voltage MDCT.  
 
In Study II, one of the main clinical consequences of the findings is that our 
classification system is potentially a very useful clinical tool. The focus of this 
classification has been on the main peripancreatic vessels, which are the critical 
anatomical structures around the pancreatic gland because the involvement of these 
structures will have immediate consequences for the ensuing therapeutic strategies 
and surgical planning.  
 
In Study III, the main clinical consequence of our findings, in agreement with the 
findings of Study I, is the improved tumor conspicuity with the use of the low-tube-
voltage MDCT. Moreover, tumor conspicuity can be increased by combining low tube-
voltage with high iodine-load. 
 
In Study IV, there are several clinical consequences. First, as it is well known that the 
surgical outcome is surgeon depended [112], the selection of more skillful and 
experienced surgeon should be considered, in those cases assessed preoperatively as 
having a high risk for PF. Second, in certain situations where the risk for postoperative 
PF formation is high, carrying out a subtotal pancreatectomy may be the wisest option. 
In doing so, the PF risk decreases while the endocrine function of the gland is 
preserved, as the distribution of the islet cells is twice as high in the tail of the pancreas 
as in the head and body [113]. Third, having in mind, which patients are in higher risk 
for developing PF, can this group of patients be monitored and followed up more 
closely postoperatively.  
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6 CONCLUSIONS 
The conclusions of this thesis regarding:  
 
1. Detection: Normal-tube-voltage 64-chanel MDCT is adequate for detecting 
tumors of 8 and 10 mm (Study I). However, the detection of smaller tumors 
can be improved when low-tube-voltage is applied (Study I). Additionally, 
tumor conspicuity is significantly better when low tube-voltage is combined 
with high iodine-load (Study III).  
 
2. Local staging: The interobserver agreement between radiologists with 
different expertise levels is almost perfect in assessing the local tumor staging 
based on the institutional MDCT examination protocol and classification 
system (Study II). There is a high correlation between the local staging 
assessment and the surgical outcome based on the same protocol and 
classification (Study II). Normal-tube-voltage normal-iodine-load protocol is 
similar to low-tube-voltage with or without high-iodine-load protocol in local 
resectability assessment (Study III). Slight arterial overestimation may occur 
with all protocols (Study III).  
 
3. Prediction: Preoperative CT and/or MRI, by measuring the PRV and PDW, 
can predict the risk for the most common and major postoperative 
complication, which is the PF.  
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7 FUTURE ASPECTS 
Even though the importance of 64-channel MDCT for tumor detection, 
characterization, staging and prediction of post-operative complications is well-
accepted due to its relatively high specificity, sensitivity and high interobserver 
agreement, there is still potential for further improvement.   
Recent revolutionary technological developments in MDCT enabling the use of dual 
energy (DE) MDCT and perfusion CT offer the possibility to exploit spectral 
information for diagnostic purposes [114]. 
 
Our studies (Studies I and III) have shown that scanning at low tube-voltage improves 
spatial resolution and image contrast at the expense of image noise. The main principle 
of DE-MDCT is the acquisition of CT data using two different photon spectra (at 
80/100 kV and 140 kV) within a single acquisition. This has the potential to combine 
the advantages of low and high tube-voltage, which are the increased image contrast 
and the low image noise, respectively.  
 
Hitherto, many applications of the DE technique have been tested in abdominal 
imaging and particularly in pancreatic imaging. DE-MDCT energy and perfusion CT 
are two recent CT techniques for abdominal imaging that may provide additional 
information about the tissue being examined in combination with the morphological 
findings [115]. One limitation of single-energy MDCT is the considerable overlap in 
material attenuation resulting in potential ambiguity for discriminating between 
different materials [116]. DE-MDCT has the potential to decrease this by interrogating 
the material-specific attenuation properties at different energy levels [116]. A quite 
recent study showed that perfusion CT can predict tumor grading, since high grade 
PDAC has significantly higher peak enhancement intensity and blood volume perfusion 
parameters [117]. Mileto et al. have recently shown that by using the DE technique, 
virtual non-contrast images reconstructed from a single-phase contrast enhanced DE-
MDCT can replace the conventional NCP with no effect in the image quality. 
Concurrently the radiation dose is reduced significantly compared to the standard 
single-energy protocol [118]. Patients with hereditary pancreatic cancer who undergo 
annual CT examination of the pancreas will certainly benefit from such protocols. 
Macari et al. have shown that pancreatic tumor conspicuity at 80 kV increases 
significantly compared with the weighted-average 120kV [119]. However, these 
observations were done in the portal venous phase and the effect of perfusion CT was 
not taken into consideration. 
 
Despite the fact that few articles have been published on the impact of DE-MDCT and 
perfusion CT in pancreatic cancer imaging, further prospective, well-designed clinical 
trials are needed to investigate the validity of these methods relative to tumor diagnosis, 
staging and prediction of postoperative complications. 
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